Zosano Pharma Corp

Zosano Pharma — Investor Presentation (February 2020)

35 slides from Zosano Pharma's investor presentation, Feb 11, 2020

  1. Slide 1: Corporate Presentation February 2020

    Exhibit 99.1 Corporate Presentation February 2020 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | ConfidentialExhibit 99.1 Corporate Presentation February 2020 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements TM This presentation contains forward-looking statements regarding Zosano’s technology and product candidates, including Qtrypta and C213, and other future events and expectations. Readers are urged to consider statements that include the words may, will, would, could, sho

  3. Slide 3: Zosano Pharma: Working to Transform How Drugs Are Delivered

    Zosano Pharma: Working to Transform How Drugs Are Delivered Differentiated OUR MISSION Technology Advancing Patient Care and Transforming Patient Lives Through Therapies Developed Utilizing Our Proprietary Delivery Platform Significant OUR FOCUS Clinical Late Stage Clinical Development Programs for

  4. Slide 4: Executive Summary and Recent Highlights

    Executive Summary and Recent Highlights ▪ Technology (formerly MACROFLUX) developed at ALZA Corp/J&J Transformative ▪ 26 Patent Families and IP Protection Delivery Platform ▪ First and Only Microneedle Patch to be included in an NDA Submission to the FDA 1 ▪ Migraine is ranked globally as the sevent

  5. Slide 5: Zosano's Intracutaneous Drug Delivery

    Zosano’s Intracutaneous Drug Delivery Novel & Proprietary Intracutaneous patch with drug-coated microneedle array Designed to be Rapid & Consistent Designed for rapid and consistent absorption of drugs into capillary bed Designed to Minimize Stimulation Shallow penetration designed to minimize stimu

  6. Slide 6: Qtrypta Designed for Optimization of Therapy Delivery

    Qtrypta™ Designed for Optimization of Therapy Delivery ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential 6Qtrypta™ Designed for Optimization of Therapy Delivery ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential 6

  7. Slide 7: Addressing Unmet Needs in Migraine

    ADDRESSING UNMET NEEDS IN MIGRAINE 7 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | ConfidentialADDRESSING UNMET NEEDS IN MIGRAINE 7 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential

  8. Slide 8: Migraine is Highly Prevalent, Debilitating and Costly

    Migraine is Highly Prevalent, Debilitating and Costly 1 1 Costly Debilitating Prevalent ▪ 90% Unable to ▪ $36B in Lost ▪ 3rd Most Prevalent 2 Function Normally Productivity Disorder in the World ▪ 1.2 MM ER Visits ▪ $5.4B in ▪ Impacts ~25% of per Year Treatment U.S. Households 1 ▪ 25% of women Costs

  9. Slide 9: Patients Want Fast and Complete Pain Relief That Lasts

    Patients Want Fast and Complete Pain Relief That Lasts Unmet Acute Treatment Needs 2 The Qtrypta Solution 1 From the 2017 MAST Study Pain Relief 74% Inadequate Treatment Response 81% at 2 Hours Pain Relief at 65% Rapid Headache Onset 46% 30 Minutes Achieved PF 49% Inadequate Pain Freedom 42% at 2 Ho

  10. Slide 10: Triptans Are and Will Remain the Standard of Care

    Triptans Are and Will Remain the Standard of Care Yet Current Triptan & DHE Formulations Fail To The 2018 American Headache Meet Patient Needs Society Position Statement On Integrating New Migraine Treatments 1 Into Clinical Practice . 2 Nausea Affects Treatment 24% ▪ treat early after the onset of

  11. Slide 11: Qtrypta Clinical Results From Phase 2/3 ZOTRIP Study

    Qtrypta Clinical Results From Phase 2/3 ZOTRIP Study Activity Efficacy Results Results Reported Observed 78% Pain Relief Peak Plasma at 24 Hours 15 Mins Concentration Reported Reported Pain 81% Pain Relief 71% Relief at 48 23% of Patients at 2 Hours Hours Achieved Pain Relief Reported 42% Pain Freed

  12. Slide 12: Clinically Significant Results on Pain Freedom and MBS in Phase 2/3 Study

    Clinically Significant Results on Pain Freedom and MBS in Phase 2/3 Study Successful Achievement of Co-Primary Endpoints 80% 60% p=<0.0009 TG = 25.4 68.3% 40% p=<0.0001 TG = 27.2 41.5% 42.9% 20% 14.3% 0% Pain Freedom MBS Qtrypta 3.8mg Placebo Spierings ELH et al. Randomized, double-blind, placebo-co

  13. Slide 13: Qtrypta Showed Rapid and Sustained Effect With One Dose

    Qtrypta Showed Rapid and Sustained Effect With One Dose Pain Freedom 30 Minutes to 48 Hours ** ** 69.5% 64.6% ** 62.2% ** 60% 54.9% ** 51.2% ** 41.5% 40% ** 26.8% * 17.1% 20% 7.3% 0% 30 minutes 45 minutes 1 hour 2 hour 3 hour 4 hour 12 hours 24 hours 48 hours Qtrypta Placebo Spierings ELH et al. Ran

  14. Slide 14: Pain Relief Through 48 Hours

    Pain Relief Through 48 Hours Pain Relief 15 Minutes to 48 Hours 71.0% ** 78.0% ** 82.9% 80.5% 81.7% ** 80.5%** ** ** 80% 68.3% * 60% 56.1% 46.3% 40% 23.2% 20% 0% 15 minutes 30 minutes 45 minutes 1 hour 2 hour 3 hour 4 hour 12 hours 24 hours 48 hours Qtrypta Placebo Spierings ELH et al. Randomized, d

  15. Slide 15: Migraine-ACT Results in Long Term Safety Trial

    Migraine-ACT Results in Long Term Safety Trial Proportion of Participants Who Answered “Yes” at 48 Weeks Does Your Migraine Are You Comfortable 95% Medication Work 93% Enough With Your Consistently in the Majority Medication to Be Able To of Your Attacks Plan Your Daily Activities Migraine-ACT quest

  16. Slide 16: Qtrypta was Well Tolerated in the Long-Term Safety Study

    Qtrypta was Well Tolerated in the Long-Term Safety Study Platform Presentation at International Headache Congress (IHC) 2019 * ▪ Most Common Adverse Events were redness/swelling. ▪ 95% were mild ▪ 80% resolved within 48 hours ▪ Less than 2% of patients reported triptan-like sides effects such as * d

  17. Slide 17: Emerging Treatments Ubrogepant and Rimegepant

    Emerging Treatments Ubrogepant and Rimegepant The 2018 American Headache Society Position Statement On 2 Integrating New Migraine Treatments ▪ 19.2 – 21.8% Pain Freedom at 2 Hours Into Clinical Practice. ▪ Potential Liver Toxicity Concerns Patients who have contraindications to the use of triptans o

  18. Slide 18: Commercial Strategy

    COMMERCIAL STRATEGY 18 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | ConfidentialCOMMERCIAL STRATEGY 18 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential

  19. Slide 19: >8MM Migraine Patients Represent a Large, Focused Opportunity

    >8MM Migraine Patients Represent a Large, Focused Opportunity 37+ million Suffer Resulting in >150 million # Specialists Treating From Migraine Migraine-Days • Family Medicine ~60m ~240k • General Practice HA-days 29 million with 0 - 4 • Neurologists ~35m ~30k migraines/ month • “Specialized GPs” ~6

  20. Slide 20: Market Research Completed in Early 2020

    Market Research Completed in Early 2020 1 ▪ Physician Market Research ▪ Blinded ▪ 100 neurologists and headache specialists who treat over 300 migraine patients per month on average ▪ Product profile of Qtrypta referenced as “Product X” in market research ▪ Included new entrants in acute treatment o

  21. Slide 21: Patients Continue to Suffer Even with New Preventives

    1 Patients Continue to Suffer Even with New Preventives Neurologists Have a Difficult To Treat Population Migraine Patients Strongly Agree They Have a Treated Monthly (Avg.) Substantial “Difficult To Treat” 67% Migraine Patient Population 300+ Of Physician’s Patients are on 51% of These AND… Prevent

  22. Slide 22: Neurologists Strongly Agree That Unmet Need Remains

    1 Neurologists Strongly Agree That … Still an UNMET NEED in the acute setting even 79% in patients that respond to preventive therapy Patients with morning migraine need a therapy with FAST ONSET and high success of PAIN 79% RELIEF Using a NON-ORAL therapy in the difficult to treat population is ide

  23. Slide 23: Perspectives on Product Profiles from Neurologists

    1 Perspectives on Product Profiles from Neurologists Indicated Indicated Product X Likelihood to Possesses High Prescribe 58% 54% Clinical Utility Product X 39% 43% 49% 46% Lasmiditan Lasmiditan Product Y Product Y 1.Trinity Market Research (2020). Zosano Pharma Proprietary Neurologist and Headache

  24. Slide 24: Payer Feedback On Market Access For Qtrypta, if Approved

    Payer Feedback On Market Access For Qtrypta, if Approved Top Line National Payer and PBM Market Research Findings ▪ Recognition that migraine patients Need Non-Oral Treatment Options ▪ Likely formulary placement will Be Tier 3 or Non-Preferred after Failure of Two Generic Triptans ▪ Formulary placem

  25. Slide 25: Portfolio Expansion

    PORTFOLIO EXPANSION ZSCP2020-2.2 25 Copyright © 2020 Zosano Pharma | ConfidentialPORTFOLIO EXPANSION ZSCP2020-2.2 25 Copyright © 2020 Zosano Pharma | Confidential

  26. Slide 26: Significant Unmet Need in Cluster Headache

    Significant Unmet Need in Cluster Headache 1 3 Highly Disabling Chronic Neurological Condition Short-lasting Headache Attacks Characterized By ▪ Severe Unilateral Temporal/orbital Pain ▪ Recognized as Most Severe Pain Known ▪ Ipsilateral Autonomic Symptoms to Humans 2 ▪ Lasting 15–180 Minutes (when

  27. Slide 27: Cluster Headache (C213): Clinical Trial Program

    Cluster Headache (C213): Clinical Trial Program Phase 2/3 Clinical Trial Design Cluster Patients: 120 Population: Chronic or episodic cluster headache sufferers Each cluster headache sufferer will take a single dose to treat a Design: qualifying headache Dosing: 1.9 mg and 3.8 mg vs placebo (1:1:1)

  28. Slide 28: Pipeline Expansion

    PIPELINE EXPANSION 28 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | ConfidentialPIPELINE EXPANSION 28 ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential

  29. Slide 29: Leveraging Platform & Clinical Validation for Pipeline Expansion

    Leveraging Platform & Clinical Validation for Pipeline Expansion PRE-CLINICAL & CLINICAL PROOF-OF-CONCEPT ▪ Small Molecules − Zolmitriptan (NDA submitted) ▪ Hormones, Peptides & Proteins − Clinical: Glucagon (Phase 2), PTH (Phase 2), Desmopressin (Phase 1), − Preclinical: EPO, HGH ▪ Prophylactic Vac

  30. Slide 30: Zosano Pharma Microneedle Array Drug Delivery System

    Zosano Pharma Microneedle Array Drug Delivery System Ideal solution for delivery of peptides, proteins and hydrophilic drugs ▪ First generation transdermal patches limited to hydrophobic molecules ▪ Low bioburden manufacturing and terminal sterilization mitigates need for aseptic manufacturing ▪ Roo

  31. Slide 31: Dosage Flexibility Enabled by Formulation, Process and Design

    Dosage Flexibility Enabled by Formulation, Process and Design 1. Formulation – Product formulation defines capability of coating on the microneedle substrate. Kept constant within a product family Formulation & 2. Process – Multiple dips increase coated amount per microneedle. Once passes (& coating

  32. Slide 32: Experienced Management Team

    Experienced Management Team Name Title Experience Steven Lo Chief Executive Officer VP, Clinical Development & Donald Kellerman, PharmD Medical Affairs Christine Matthews Interim Chief Financial Officer Hayley Lewis SVP, Operations Dushyant Pathak, PhD SVP, Business Development ZSCP2020-2.2 Copyrigh

  33. Slide 33: Board of Directors

    Board of Directors Name Title Experience John P. Walker Chairman, Zosano Pharma Steven Elms Managing Partner, Aisling Capital Linda Grais, MD, JD Director, Zosano Pharma Kenneth R. Greathouse Director, Zosano Pharma President and Chief Executive Joseph Hagan Officer, Regulus Therapeutics Inc. Presid

  34. Slide 34: Executive Summary

    Executive Summary ▪ Submission of NDA to the FDA for the acute treatment Near-term of migraine in December 2019 Milestones ▪ Initiated Phase 2/3 efficacy trial for the acute treatment Achieved of cluster headache Clinically ▪ Qtrypta, if approved, may have the potential to offer fast, Significant Ph

  35. Slide 35: ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential 35ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential 35

    ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential 35ZSCP2020-2.2 Copyright © 2020 Zosano Pharma | Confidential 35

Zosano Pharma — Investor Presentation (February 2020) on 6ix